Literature DB >> 15293102

Lupus anticoagulant, factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis.

Imad Uthman1, Ismail Khalil, Raja Sawaya, Ali Taher.   

Abstract

We describe the case of a young Lebanese woman with systemic lupus erythematosus (SLE) and a positive lupus anticoagulant (LAC) who developed right internal jugular vein and sigmoid sinus thrombosis. Coagulation studies showed that in addition to the LAC the patient was heterozygous for the factor V (FV) Leiden mutation, and C677T mutation of the methylenetetrahydrofolate reductase gene. The high prevalence of FV Leiden in the eastern Mediterranean region suggests that we should probably screen our SLE patients in this area, especially those with anticardiolipin antibodies and/or LAC who have no history of thrombosis, for this and other thrombophilia markers. The detection of such abnormalities may have major practical consequences for the long-term management of these patients to prevent further thrombotic episodes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293102     DOI: 10.1007/s10067-004-0893-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

1.  High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation?

Authors:  A Taher; I Khalil; A Shamseddine; F El-Ahdab; A Bazarbachi
Journal:  Thromb Haemost       Date:  2001-08       Impact factor: 5.249

2.  The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese.

Authors:  N Irani-Hakime; H Tamim; R Kreidy; W Y Almawi
Journal:  Am J Hematol       Date:  2000-09       Impact factor: 10.047

3.  Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children.

Authors:  G Kenet; S Sadetzki; H Murad; U Martinowitz; N Rosenberg; S Gitel; G Rechavi; A Inbal
Journal:  Stroke       Date:  2000-06       Impact factor: 7.914

4.  Cerebral venous thrombosis with lupus anticoagulants. Report of two cases.

Authors:  S R Levine; S Kieran; K Puzio; H Feit; S C Patel; K M Welch
Journal:  Stroke       Date:  1987 Jul-Aug       Impact factor: 7.914

Review 5.  Cerebral venous thrombosis and anticardiolipin antibodies.

Authors:  J R Carhuapoma; P Mitsias; S R Levine
Journal:  Stroke       Date:  1997-12       Impact factor: 7.914

6.  Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Jean-Charles Piette; Josep Font; Munther A Khamashta; Yehuda Shoenfeld; María Teresa Camps; Soren Jacobsen; Gabriella Lakos; Angela Tincani; Irene Kontopoulou-Griva; Mauro Galeazzi; Pier Luigi Meroni; Ronald H W M Derksen; Philip G de Groot; Erika Gromnica-Ihle; Marta Baleva; Marta Mosca; Stefano Bombardieri; Frédéric Houssiau; Jean-Christophe Gris; Isabelle Quéré; Eric Hachulla; Carlos Vasconcelos; Beate Roch; Antonio Fernández-Nebro; Marie-Claire Boffa; Graham R V Hughes; Miguel Ingelmo
Journal:  Arthritis Rheum       Date:  2002-04

7.  Superior vena cava occlusion in a patient with antiphospholipid antibody syndrome.

Authors:  Y Tomer; A Kessler; A Eyal; A Many; Y Shoenfeld
Journal:  J Rheumatol       Date:  1991-01       Impact factor: 4.666

Review 8.  Central nervous system involvement in the antiphospholipid (Hughes) syndrome.

Authors:  G Sanna; M L Bertolaccini; M J Cuadrado; M A Khamashta; G R V Hughes
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

9.  Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.

Authors:  M A Deschiens; J Conard; M H Horellou; A Ameri; M Preter; F Chedru; M M Samama; M G Bousser
Journal:  Stroke       Date:  1996-10       Impact factor: 7.914

10.  Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies.

Authors:  Nikhil Chopra; Sharon Koren; Wenda L Greer; Paul R Fortin; Joyce Rauch; Isabelle Fortin; Jean-Luc Senécal; Peter Docherty; John G Hanly
Journal:  J Rheumatol       Date:  2002-08       Impact factor: 4.666

  10 in total
  6 in total

Review 1.  Antithrombotic therapy for stroke in young adults.

Authors:  Jeremy R Payne; Bruce Coull
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

2.  Thrombophilic risk factors among 16 Lebanese patients with cerebral venous and sinus thrombosis.

Authors:  Zaher K Otrock; Ali T Taher; Wael A Shamseddeen; Rami A Mahfouz
Journal:  J Thromb Thrombolysis       Date:  2007-09-06       Impact factor: 2.300

3.  Cerebral venous thrombosis in the mediterranean area in children.

Authors:  S Menascu; A Lotan; B Ben Zeev; U Nowak-Gottl; G Kenet
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-07-08       Impact factor: 2.576

4.  Cerebral venous-sinus thrombosis: a case series analysis.

Authors:  Nahid Ashjazadeh; Afshin Borhani Haghighi; Maryam Poursadeghfard; Hoseinjan Azin
Journal:  Iran J Med Sci       Date:  2011-09

5.  Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study.

Authors:  Mohammad Saadatnia; Mansour Salehi; Ahmad Movahedian; Seyed Ziaeddin Samsam Shariat; Mehri Salari; Marzieh Tajmirriahi; Elham Asadimobarakeh; Rasoul Salehi; Gilda Amini; Homa Ebrahimi; Ehsan Kheradmand
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

6.  Cerebral Vein Thrombosis in the Antiphospholipid Syndrome: Analysis of a Series of 27 Patients and Review of the Literature.

Authors:  Alba Jerez-Lienas; Alexis Mathian; Jenifer Aboab; Isabelle Crassard; Miguel Hie; Fleur Cohen-Aubart; Julien Haroche; Denis Wahl; Ricard Cervera; Zahir Amoura
Journal:  Brain Sci       Date:  2021-12-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.